United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso® in Idiopathic Pulmonary Fibrosis

Core Insights - United Therapeutics Corporation announced a webcast to review data from the successful TETON-2 pivotal study evaluating nebulized Tyvaso® (treprostinil) Inhalation Solution for treating idiopathic pulmonary fibrosis (IPF) [1] Group 1 - The webcast is scheduled for September 28, 2025, at 12:30 p.m. Eastern Time [1] - Steven D. Nathan, M.D., will be presenting during the webcast [1]